Welcome to our dedicated page for Freenome SEC filings (Ticker: PCSC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Freenome's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Freenome's regulatory disclosures and financial reporting.
Freenome, Inc. reported that on July 20, 2026, in connection with the closing of its business combination with Freenome Holdings, Inc., Perceptive Capital Solutions Holdings, an entity whose board includes Michael Altman, converted 2,066,250 Class B Ordinary Shares into 2,066,250 shares of Common Stock. Following this one-for-one share-class conversion, Perceptive Capital Solutions Holdings indirectly held 2,352,500 shares of Common Stock.
RA Capital Management, L.P., together with Peter Kolchinsky, Rajeev Shah and affiliated funds, beneficially owns 15,367,270 shares of Freenome, Inc. common stock, representing 14.3% of the 107,446,814 shares outstanding as of the July 20, 2026 business combination closing.
The stake is held across RA Capital Healthcare Fund, L.P. (12,230,122 shares), several Nexus funds and a managed account. The investors received Freenome shares in the business combination for an aggregate prior equity investment of $218,999,969 and purchased additional PIPE shares for $52,553,760 at $10 per share. An investor rights agreement provides resale registration, demand and piggyback rights, while a lock-up restricts transfers for six months after closing. The position is for investment purposes, though the investors may adjust holdings and engage with management, and Kolchinsky serves as a director.
RA Capital Management, L.P. and affiliated investment funds reported indirect acquisitions of Freenome, Inc. common stock on July 20, 2026. Several blocks, including 6,561,711 shares, were received pursuant to a Business Combination with Old Freenome, while others, such as 4,918,411 shares, were acquired at $10.00 per share. The shares are held by RA Capital Healthcare Fund, the Nexus funds, and a separately managed account, with RA Capital as investment manager; Dr. Peter Kolchinsky and Mr. Rajeev Shah disclaim beneficial ownership beyond their respective pecuniary interests.
RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Dr. Peter Kolchinsky and Mr. Rajeev Shah report indirect ownership of 750,000 shares of Freenome, Inc. common stock, held directly by the Fund as of July 20, 2026.
The Adviser acts as investment manager to the Fund, whose general partner is RA Capital Management GP, LLC. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership except to the extent of respective pecuniary interests.
Freenome, Inc. is being removed from listing and registration on the Nasdaq Stock Market LLC for its Class A Ordinary Shares under Section 12(b) of the Securities Exchange Act of 1934. Nasdaq certifies that both the exchange and the issuer have complied with the applicable rules for this voluntary withdrawal.
Perceptive Capital Solutions Corp held an extraordinary general meeting on July 15, 2026, where shareholders approved the Business Combination Proposal, Domestication Proposal, new governing documents, Nasdaq listing-related proposal, and new equity incentive and employee stock purchase plans tied to a Business Combination involving PCSC and Freenome.
The approvals made an adjournment vote unnecessary. The meeting had a quorum, with 5,645,461 Class A and 2,156,250 Class B ordinary shares represented, about 75.65% of voting power as of the June 12, 2026 record date. Total shares outstanding then were 10,313,492, including 8,157,242 Class A shares. PCSC notes that completing the Business Combination and related transactions remains subject to conditions and risks discussed in its proxy materials and SEC reports.
Perceptive Capital Solutions Corp. held an extraordinary general meeting on July 15, 2026, where shareholders approved the Business Combination Proposal with Freenome and related items, including the Domestication Proposal, updated governing documents, Nasdaq listing proposal, an equity incentive plan and an employee stock purchase plan.
Holders of 5,645,461 Class A and 2,156,250 Class B shares, representing approximately 75.65% of voting power as of the June 12, 2026 record date, were present, constituting a quorum. One proposal, for example, received 6,819,879 votes for, 980,832 against and 1,000 abstaining. An adjournment proposal was not needed because the required items had sufficient support.
Perceptive Capital Solutions Corp., a SPAC, reported a small net loss of $166,692 for the six months ended June 30, 2026, versus net income in the prior-year period, driven by higher general and administrative expenses of $1,800,159 and lower investment income from its trust assets. For the quarter, it recorded a net loss of $114,943.
Total assets were $85.8 million, almost entirely the $85.1 million held in the trust account. Cash outside the trust was $437,369, and the company had a working capital deficit of $2,885,923. After the June 10, 2026 extension vote, 754,008 Class A shares were redeemed for about $8.16 million, leaving 7,870,992 Class A shares subject to possible redemption at approximately $10.81 per share.
The deadline to complete a business combination was extended from June 13, 2026 to June 13, 2027, but management states that liquidity constraints and the mandatory liquidation date raise substantial doubt about the company’s ability to continue as a going concern. The company is pursuing a planned merger with Freenome Holdings, Inc. at an implied equity value of $725 million, supported by a committed PIPE financing of 24,000,000 shares of New Freenome common stock at $10.00 per share, or $240 million, expected to close in the second half of 2026 if conditions are met.
Perceptive Capital Solutions Corp filed a prospectus supplement registering up to 82,313,492 shares of common stock in connection with its proposed business combination and domestication to Delaware, after which it will be renamed Freenome, Inc.
The supplement, dated July 9, 2026, revises the extraordinary general meeting to 10:00 a.m. Eastern Time on July 15, 2026, extends the redemption deadline to 5:00 p.m. Eastern Time on July 13, 2026, and permits in-person attendance by reservation. It also adds clinical-validation results for the updated SimpleScreen v2 test, reporting weighted sensitivities of 80.4% for CRC (N=89), 18.2% for advanced precancerous lesions (N=1,570), and 41.9% for APLs with high-grade dysplasia (N=157); specificity was 90%. The supplement states the data are preliminary and management review is ongoing.
Freenome and Perceptive Capital Solutions Corp. disclosed top-line results for SimpleScreen CRC v2 presented July 9, 2026, reporting that the v2 assay met its pre-specified primary and secondary endpoints. The US Census‑adjusted sensitivity for colorectal cancer (CRC) was 80.4% (89 cases, 95% CI 70.2%–87.7%) and for advanced precancerous lesions (APL) was 18.2% (1,570 cases, 95% CI 16.3%–20.4%).
The PREEMPT cohort (evaluables n = 9,070) showed improved APL and high‑grade dysplasia (HGD) detection versus v1 while maintaining CRC sensitivity in line with v1. Modelled lifetime projections per 100,000 screened estimate 9.5% fewer CRC cases and deaths and 7.7% more life‑years gained versus v1.